Search For "drug controller general of india"
Mylan gets DCGI nod for remdesivir in India, to launch at Rs 4,800 per via
Updated : 1 year, 10 months ago IST
Bengaluru (Karnataka) [India], July 7 (ANI): Global pharmaceutical major Mylan has got approval for its remdesivir from the Drug Controller General of India (DCGI) and will launch a generic version of Gilead Sciences' COVID-19 anti-viral in the country at Rs 4,800 for 100 mg/vial.
Read More
DCGI permits human clinical trials for COVID-19 vaccine of Zydus Cadila
Updated : 1 year, 10 months ago IST
New Delhi [India], July 3 (ANI): The Drug Controller General of India (DCGI) on Thursday granted permission to pharma giant Zydus Cadila to conduct phase I and phase II human clinical trials for COVID -19 vaccine, a top government official told ANI.
Read More
DCGI gives nod to Mylan labs to manufacture remdesivir for 'restricted eme
Updated : 1 year, 10 months ago IST
New Delhi [India], July 2 (ANI): The Drug Controller General of India (DCGI) has granted permission to Mylan laboratories to manufacture and market the anti-viral drug remdesivir for 'restricted emergency use' on hospitalised COVID-19 patients, a senior government official said on Thursday.
Read More
DCGI gives nod to Bharat Biotech to conduct phase I & II Human clinica
Updated : 1 year, 10 months ago IST
New Delhi [India], June 30 (ANI): The Drug Controller General of India (DCGI) has granted permission to Bharat Biotech International Limited (BBIL) to conduct Phase I and II Human clinical trials to develop an indigenous vaccine for COVID-19 -- in the name COVAXIN.
Read More
Glenmark, Cipla stocks surge after nod to launch drugs for mild-to-moderat
Updated : 1 year, 11 months ago IST
Mumbai (Maharashtra) [India], June 22 (ANI): Glenmark Pharmaceuticals' share price surged 30 per cent on Monday to Rs 531.80 per unit after it became the first pharmaceutical company in India to receive regulatory approval to make and sell oral antiviral drug favipiravir for treating mild-to
Read More
Anti-viral drug favipiravir gets DGCI nod for 'restricted emergency use' i
Updated : 1 year, 11 months ago IST
New Delhi [India], June 19 (ANI): The Drug Controller General of India (DCGI) has granted permission to anti-viral drug favipiravir for "restricted emergency use" in mild to moderate cases of COVID-19, a senior government official confirmed to ANI.
Read More
Remdesivir effective in treating critical COVID-19 patients, says senior p
Updated : 1 year, 11 months ago IST
New Delhi [India], June 4 (ANI): Former honorary physician to the President of India and senior physician at Ganga Ram hospital Dr Mohsin Wali has welcomed the move of the Drug Controller General of India to give permission for emergency use of Remdesivir to treat COVID-19 patients and sa
Read More
COVID-19: Pharma giants seek DCGI's approval to manufacture, sell Remdesiv
Updated : 1 year, 11 months ago IST
New Delhi [India], June 4 (ANI): Two domestic pharmaceutical firms--Mylan and Jubilant Life Sciences have approached the country's top drug regulator--Drug Controller General of India (DCGI) to seek its approval to manufacture and sell anti-viral drug 'Remdesivir' in India to combat COVID-19
Read More
Glenmark begins phase 3 of clinical trials on antiviral Favipiravir for CO
Updated : 2 years ago IST
Mumbai (Maharashtra) [India], May 12 (ANI): Glenmark Pharmaceuticals has initiated phase three of clinical trials in India on antiviral tablet Favipiravir, becoming the first company in the country to do so.
Read More
CSIR to begin two clinical drug trials to combat COVID-19
Updated : 2 years ago IST
New Delhi [India], May 8 (ANI): The Council for Scientific and Industrial Research (CSIR) has received approval from Drug Controller General of India (DGCI) for its two clinical trial drugs - 'favipiravir' and 'phytopharmaceutical' - to combat coronavirus.
Read More
Zydus Cadila approaches DCGI to use hepatitis drug for COVID-19 clinical t
Updated : 2 years ago IST
New Delhi [India], May 5 (ANI): The country's top drug regulator, Drug Controller General of India (DCGI), has received an application from Zydus Cadila, the leading global pharmaceutical company in India, to conduct clinical trial using antiviral drug 'Pegylated Interferon Alpha-2b' in adul
Read More
COVID-19: AIIMS Bhopal conducting multicentric study on Mycobacterium w
Updated : 2 years ago IST
Bhopal (Madhya Pradesh) [India], April 30 (ANI): A multicentric study on the use Mycobacterium w (Mw), heat-killed Mycobacterium indicus pranii, as an adjunct to the treatment of coronavirus is being conducted at AIIMS Bhopal with the approval of Drug Controller General of India.
Read More